Enrich Biosystems
Private Company
Funding information not available
Overview
Enrich Biosystems is a private, early-stage life science tools company founded in 2016, specializing in functional cell screening. Its flagship TROVO platform combines 3D-printed hydrogel microwells, long-term live-cell imaging, and AI-driven analysis to identify and physically retrieve rare, high-performing cells without fluidics. The company targets the growing markets in cell therapy development, antibody discovery, and single-cell omics, positioning itself as an enabling technology provider for biopharmaceutical R&D.
Technology Platform
TROVO system: A benchtop instrument for high-throughput functional cell screening and live-cell retrieval. It uses microgel lithography to 3D print hydrogel microwells for cell culture, enables long-term live-cell imaging, and employs AI-powered image analysis (CellProfiler/CellPose) to identify and physically retrieve cells based on functional behavior, all in a fluidics-free workflow.
Opportunities
Risk Factors
Competitive Landscape
Enrich competes in the cell analysis and isolation market. Direct competitors include companies offering high-content screening systems (e.g., PerkinElmer, Molecular Devices) and advanced cell sorters (e.g., BD Biosciences, Bio-Rad). Its unique combination of long-term functional imaging, AI analysis, and gentle retrieval in standard plates differentiates it from both imaging-only platforms and marker-based sorters, but it must convince customers of its integrated value over piecing together solutions from these larger players.